Clinuvel Pharmaceuticals Ltd traded at 11.06 this Friday February 6th, decreasing 0.67 or 5.71 percent since the previous trading session. Looking back, over the last four weeks, Clinuvel Pharmaceuticals lost 9.79 percent. Over the last 12 months, its price fell by 3.57 percent. Looking ahead, we forecast Clinuvel Pharmaceuticals Ltd to be priced at 10.78 by the end of this quarter and at 10.13 in one year, according to Trading Economics global macro models projections and analysts expectations.
Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).